Philogen Considers Partnering As Two Lead Assets Near Market

Bolstering Targeted Oncology Expertise

20 Oct 2022

• By Ayisha Sharma

The Swiss-Italian biotech firm’s two lead assets for cancer are expecting pivotal readouts next year, prompting it to consider partnering strategies and further substantiating its targeted R&D approach.

3D image of cytokine — Philogen Has Expert Knowledge In Combining Antibodies With Cytokines • Source: Shutterstock

Philogen S.p.A.’s two lead assets, Nidlegy and Fibromun, are approaching Phase III readouts next year and the firm is mulling its commercialization strategy as its payload-ligand approach to drug development gains traction.

The Swiss-Italian biotech firm was founded in 1996 and has since teamed up with the likes of Janssen Biotech...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

28 Jul 2025

• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

GSK Gains Hengrui’s PDE3/4 inhibitor, Options For 11 Early Assets In Potential $12bn Deal

28 Jul 2025

• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Quick Listen: Scrip’s Five Must-Know Things

28 Jul 2025

• By Ian Haydock

In this week's episode: Sanofi’s Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech’s Columvi; and an interview with Novavax.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

25 Jul 2025

• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

25 Jul 2025

• By Alaric DeArment

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.